Deutsche Bank AG Buys 171,735 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Deutsche Bank AG has increased its stake in Amneal Pharmaceuticals by 128.3%, owning 305,621 shares valued at approximately $2.56 million.
• Analysts have set an average price target of $11.60 for Amneal Pharmaceuticals, with five analysts rating the stock as a "Buy".
• Insider transactions show executives sold shares totaling $666,037 and $302,595 recently, reflecting a decrease in their ownership stakes.

Deutsche Bank AG boosted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 128.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 305,621 shares of the company's stock after acquiring an additional 171,735 shares during the period. Deutsche Bank AG owned 0.10% of Amneal Pharmaceuticals worth $2,561,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in AMRX. Legal & General Group Plc increased its stake in Amneal Pharmaceuticals by 5.0% during the 4th quarter. Legal & General Group Plc now owns 150,709 shares of the company's stock worth $1,194,000 after acquiring an additional 7,231 shares during the period. Raymond James Financial Inc. bought a new position in Amneal Pharmaceuticals during the 4th quarter worth $2,946,000. Barclays PLC increased its stake in Amneal Pharmaceuticals by 18.9% during the 4th quarter. Barclays PLC now owns 352,494 shares of the company's stock worth $2,792,000 after acquiring an additional 56,110 shares during the period. Mariner LLC increased its stake in Amneal Pharmaceuticals by 3,749.1% during the 4th quarter. Mariner LLC now owns 424,291 shares of the company's stock worth $3,360,000 after acquiring an additional 413,268 shares during the period. Finally, XTX Topco Ltd increased its stake in Amneal Pharmaceuticals by 75.8% during the 4th quarter. XTX Topco Ltd now owns 39,055 shares of the company's stock worth $309,000 after acquiring an additional 16,845 shares during the period. Institutional investors own 31.82% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AMRX. Wall Street Zen lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. The Goldman Sachs Group initiated coverage on Amneal Pharmaceuticals in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $11.60.

Insider Buying and Selling

In related news, EVP Nikita Shah sold 71,694 shares of the business's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $9.29, for a total transaction of $666,037.26. Following the sale, the executive vice president owned 267,235 shares in the company, valued at $2,482,613.15. The trade was a 21.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Andrew S. Boyer sold 279,244 shares of the business's stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total value of $2,619,308.72. Following the sale, the executive vice president owned 152,426 shares in the company, valued at $1,429,755.88. This represents a 64.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 456,374 shares of company stock worth $4,239,042 in the last 90 days. Insiders own 26.56% of the company's stock.

Amneal Pharmaceuticals Stock Up 0.6%

Shares of AMRX traded up $0.06 during midday trading on Friday, hitting $9.59. The company's stock had a trading volume of 1,720,973 shares, compared to its average volume of 1,697,029. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of 959.96 and a beta of 1.11. Amneal Pharmaceuticals, Inc. has a one year low of $6.68 and a one year high of $9.79. The company's fifty day simple moving average is $8.38 and its two-hundred day simple moving average is $8.01.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. On average, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.